Strategy
Alector Hands Genentech Global Rights to Its Parkinson's Enzyme Therapy for $100 Million Up Front
Milestones could reach $1.17 billion, and chief executive Arnon Rosenthal says the agreement pushes Alector's cash runway into 2029.
AF
By Anna Ferreira
Oct 5, 2026 · 2 min read
Alector said at 7 a.m. Eastern on Monday that it had granted Genentech, a member of the Roche group, a global license to AL050, its brain-penetrant glucocerebrosidase enzyme replacement therapy, for Parkinson's disease and other neurodegenerative conditions.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.